Access and Delivery of Essential Medicines

2011 Archive

A .mov player such as Quicktime is required to watch videos after 2009.

Realplayer is required to watch videos older than 2009. Free Realplayer 11 is located at: and Realplayer 10.5 is located at

List of all videos

Transforming Access and Delivery of Essential Medicines: Lessons from the Riders for Health Program

Lesley Sept-GSB Global Supply Chain Management
Mar 2011

For ADEM's last class of the quarter, we will be exploring the role that supply chains play in drug delivery and access. The role of responsible supply chain management is critical, and it is a growing field for environmental and social activism. Lesley Sept is the Associate Director of Stanford's Global Supply Chain Management Program, and she has done extensive work with socially and environmentally responsible supply chain initiatives. The program focuses on proving how responsible supply chain and business implications of SER initiatives can be economically valuable. The SER Program differs from other sustainability initiatives in that its attention is focused on assessing the impact SER initiatives have on the supply chain network (product development, sourcing, manufacturing, logistics, end-of-life). This week, Sept will be exploring the care and model provided by Riders for Health, a UK-based non-profit working to eliminate transport as an obstacle to drug delivery.

Riders for Health

In 1986, with the help of racing legend Randy Mamola, Andrea and Barry Colemanbegan looking into the role transport played in keeping children from being immunised in rural Africa. Motorcycles are well-suited for harsh African landscape, where roads are often busted, rutted or simply non-existent. With the help of Linda Paterson, Save the Children, the local governments and money raised at bike rallies in England, they set-up pilot programs in Uganda and Gambia, and helped acquire motorcycles and train riders and technicians. They built a fleet of 47 bikes in Lesotho that delivered health-care services from 1991 to 1996 without a breakdown. At the end of that period, Riders for Health became an independent organisation and had expanded into Ghana, Zimbabwe and Nigeria. They have since diversified its fleet to include refrigerated trucks, minivans and ambulances and introduced a motorcycle ambulance fitted with asidecar called the Uhuru that can be used as a mini-ambulance and double as a water pump when the bike is stationary.

Watch Video



IPIRA and UC Berkeley's Approach to Neglected Disease

Dr. Carol Mimua- IPIRA
Mar 2011

University of California, Berkeley has taken a leading stance in freeing up intellectual property for socially-motivated reasons through the office for Intellectual Property and Industry Research Alliances (IPIRA). One huge success for them has been Amyris, a biotechnology firm focused on developing treatments for neglected diseases, and which now features artemisinin, one of the most effective anti-malarial treatments on the market. However, it is not just malaria; IPIRA is taking the lead in IP liberalization for neglected disease, including dengue fever, hunger, and water purification.

Dr. Mimura is the Assistant Vice Chancellor for Intellectual Property & Industry Research Alliances (IPIRA) at the University of California, Berkeley. IPIRA is the portal to Berkeley for industry access to Berkeley’s preeminent faculty and research capabilities. ??She is a member of the Forum on Drug Discovery, Development, and Translation of the National Academies of Sciences Institute of Medicine, has served on the board of directors of the Children’s Hospital Research Institute in Oakland, CA and as a board member (the Chancellor’s alternate) of BayBio, the regional voice of biotechnology in Northern California. She was a former Executive Director of U.C. Berkeley’s Office of Technology Licensing.??Prior to her positions at U.C. Berkeley, Carol was an analyst at Technology Forecasters, a consultant to Cor Therapeutics and Genomyx, and wrote for the Genetic Engineering News. ??She holds a B.S. degree from Yale University in Molecular Biophysics & Biochemistry and Ph.D. in Biology (biochemistry and microbiology concentration) from Boston University. She was an NIH-sponsored postdoctoral fellow and research scientist at U.C. Berkeley in Biochemistry and in Chemical Biodynamics. (from

Watch Video



Healthcare Delivery in Resource-Poor Settings:
A Practical Approach

Dr. Charles Van der Horst - UNC Chapel Hill Global Health and Infectious Disease
Feb 2011

Dr. Van der Horst brings years of field experience to ADEM this Tuesday. With a clinical research background in HIV/AIDS, Dr. Van der Horst has spent the bulk of his time since 2001 working on improvement of care and patient outcomes in Malawi and South Africa.

Attached, please find a short, editorial piece Van der Horst wrote for AIDS last year exploring what must be done to fight TB/HIV in resource-poor settings.

Watch Video



Cafta And Intellectual Property In Guatemala:
Have Stronger IP Laws Reduced Access To Medicines?

Josh Rolnick and the Access and Delivery of Essential Medicines
Feb 2011

Josh is in his final year at Stanford Medical School, with a focus in Health Services and Policy Research. Having completed a JD at Yale, Josh's work at Stanford has included in-depth studies of IP Protections for Pharmaceuticals in Developing Countries, and particularly in Guatemala. Josh will be presenting his work and findings this week at ADEM.

Watch Video



HIV/AIDS medication in the developing world--
pricing, partnership, and access

Clifford Samuel (Gilead Sciences)
Feb 2011

HIV/AIDS and medication is a key focus of many institutions' efforts to improve healthcare access in the developing world. Gilead Sciences is no exception, and with a unique mix of branded distribution and generic partnerships, Gilead has made impressive strides in utilizing tiered pricing, manufacturing partnerships and an extensive network of distributors and sub-distributors to ensure expanded access to their HIV/AIDS treatments at a fraction of original price. Mr. Clifford Samuel has led this effort from his background in pharmaceuticals, and with Gilead and is now Vice President of the International Access Operations. Come hear him speak and push back with questions on these topics and on Gilead's other efforts this week.

Watch Video

Footer Links: